Patents by Inventor Pamela Albaugh
Pamela Albaugh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7371752Abstract: Disclosed are compounds of the formula: wherein X, Q, W and are as defined herein. These compounds are agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.Type: GrantFiled: December 3, 2004Date of Patent: May 13, 2008Assignee: Neurogen CorporationInventors: Guolin Cai, Pamela Albaugh, Jun Yuan
-
Patent number: 7326709Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABAA receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.Type: GrantFiled: May 30, 2006Date of Patent: February 5, 2008Assignee: Neurogen CorporationInventors: Jun Yuan, Pamela A. Albaugh, Kenneth Shaw, Alan J. Hutchison
-
Patent number: 7300945Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.Type: GrantFiled: July 12, 2005Date of Patent: November 27, 2007Assignee: Neurogen CorporationInventors: Guiying Li, Pamela Albaugh, Kevin S. Currie, Guolin Cai, Linda M. Gustavson, Kyungae Lee, Alan Hutchison, George D. Maynard, Jun Yuan, Ling Hong Xie, Manuka Ghosh, Nian Liu, George P. Luke, Scott Mitchell, Martin Patrick Allen, Spiros Liras
-
Publication number: 20070225286Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, ??K, Tt?2, ???, ?NK2?2, MKK4, c-RAF, MKK6, SAPK2? and SAPK2? kinases.Type: ApplicationFiled: June 9, 2005Publication date: September 27, 2007Inventors: Pingda Ren, Xia Wang, Guobao Zhang, Qiang Ding, Shull You, Qiong Zhang, Greg Chopiuk, Pamela Albaugh, Taebo Sim, Nathanael Gray
-
Publication number: 20070066573Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.Type: ApplicationFiled: September 27, 2004Publication date: March 22, 2007Inventors: Pamela Albaugh, Esteban Dominguez-Manzanares, Jian Hong, William Hornback, Delu Jiang, Paul Ornstein, Michelle Thompson, Eric Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Zimmerman, Ana Castano Mansanet, Larry Huffman, William Miller
-
Publication number: 20060217384Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABAA receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.Type: ApplicationFiled: May 30, 2006Publication date: September 28, 2006Applicant: Neurogen Corporation, A Corporation of the state of DelawareInventors: Jun Yuan, Pamela Albaugh, Kenneth Shaw, Alan Hutchison
-
Patent number: 7109351Abstract: Substituted pyrrolecarboxamide compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Alzheimer's dementia, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.Type: GrantFiled: August 30, 2000Date of Patent: September 19, 2006Assignee: Neurogen CorporationInventors: Pamela Albaugh, Kenneth Shaw, Alan Hutchison
-
Patent number: 7060451Abstract: Methods are provided that are useful in assaying compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. These methods involve determining the in vitro efficacy and EC50 of the compounds at defined series of cloned GABAA subtype receptors composed of specific variants of ?, ?, and ? subunits in order to develop and an activity profile for each compound. Optionally, the binding affinities of the compounds at GABAA receptors are also determined. As an additional step the in vivo effects of the compounds may be tested in animal models.Type: GrantFiled: November 9, 2001Date of Patent: June 13, 2006Assignee: Neurogen CorporationInventors: John Tallman, Dorothy Gallager, Kenneth Shaw, Geoffrey White, Marci Crandall, James Cassella, Lavanya Rajachandran, Pamela Albaugh
-
Patent number: 7053093Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABAA receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.Type: GrantFiled: January 28, 2003Date of Patent: May 30, 2006Assignee: Neurogen CorporationInventors: Jun Yuan, Pamela Albaugh, Kenneth Shaw, Alan Hutchison
-
Patent number: 7008947Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof where the variables R1, R2, A, R4, R5, R6, R6?, n, and W are defined herein. These compounds bind to the benzodiazepine site of GABAA receptors are provided and, therefore can be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals.Type: GrantFiled: March 9, 2004Date of Patent: March 7, 2006Assignee: Neurogen CorporationInventors: Guiying Li, John Peterson, Pamela Albaugh
-
Publication number: 20060025425Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.Type: ApplicationFiled: July 12, 2005Publication date: February 2, 2006Inventors: Guiying Li, Pamela Albaugh, Kevin Currie, Guolin Cai, Linda Gustavson, Kyungae Lee, Alan Hutchison, George Maynard, Jun Yuan, Ling Xie, Manuka Ghosh, Nian Liu, George Luke, Scott Mitchell, Martin Allen, Spiros Liras
-
Publication number: 20060014746Abstract: This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or Formula II: The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Processes for preparing compounds of Formula I and Formula II are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I or Formula II in combination with one or more other CNS agents to potentiate the effects of the other CNS agents.Type: ApplicationFiled: August 29, 2005Publication date: January 19, 2006Inventors: Alan Hutchison, George Maynard, Pamela Albaugh, Linghong Xie, Jun Yuan, Scott Mitchell, Vinod Singh, Manuka Ghosh, Guiying Li, Nian Liu
-
Publication number: 20050288321Abstract: The present invention provides kinase inhibitors of Formula (I).Type: ApplicationFiled: March 5, 2003Publication date: December 29, 2005Inventors: Pamela Albaugh, Jochen Ammenn, Timothy Burkholder, Joshu Clayton, Scott Conner, Brian Cunningham, Thomas Engler, Kelly Furness, James Henry, Sushant Malhotra, Mark Joseph Tebbe
-
Patent number: 6936617Abstract: This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or Formula II: The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Processes for preparing compounds of Formula I and Formula II are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I or Formula II in combination with one or more other CNS agents to potentiate the effects of the other CNS agents.Type: GrantFiled: July 12, 2002Date of Patent: August 30, 2005Assignee: Neurogen CorporationInventors: Alan Hutchison, George Maynard, Pamela Albaugh, Linghong Xie, Jun Yuan, Scott Mitchell, Vinod Singh, Manuka Ghosh, Guiying Li, Nian Liu
-
Publication number: 20050154008Abstract: Disclosed are compounds of the formula: wherein X, Q, W and are as defined herein. These compounds are agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.Type: ApplicationFiled: December 3, 2004Publication date: July 14, 2005Applicant: Neurogen Corporation, A Corporation of the State of DelawareInventors: Guolin Cai, Pamela Albaugh, Jun Yuan
-
Patent number: 6916819Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.Type: GrantFiled: December 21, 2001Date of Patent: July 12, 2005Assignee: Neurogen CorporationInventors: Guiying Li, John M. Peterson, Pamela Albaugh, Kevin S. Currie, Guolin Cai, Linda M. Gustavson, Kyungae Lee, Alan Hutchison, Vinod Singh, George D. Maynard, Jun Yuan, Ling Hong Xie, Manuka Ghosh, Nian Liu
-
Publication number: 20050014939Abstract: Substituted pyrrolecarboxamide compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Alzheimer's dementia, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.Type: ApplicationFiled: July 30, 2004Publication date: January 20, 2005Inventors: Pamela Albaugh, Kenneth Shaw, Alan Hutchison
-
Patent number: 6828329Abstract: Disclosed are compounds of the formula: wherein X, Q, W and are as defined herein. These compounds are agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.Type: GrantFiled: June 26, 2001Date of Patent: December 7, 2004Assignee: Neurogen CorporationInventors: Guolin Cai, Pamela Albaugh, Jun Yuan
-
Publication number: 20040176397Abstract: Disclosed are compounds of the formula 1Type: ApplicationFiled: March 9, 2004Publication date: September 9, 2004Applicant: Neurogen CorporationInventors: Guiying Li, John Peterson, Pamela Albaugh
-
Patent number: 6737242Abstract: Methods are provided that are useful in assaying compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. These methods involve determining the in vitro efficacy and EC50 of the compounds at defined series of cloned GABAA subtype receptors composed of specific variants of &agr;,&bgr;, and &ggr; subunits in order to develop and an activity profile for each compound. Optionally, the binding affinities of the compounds at GABAA receptors are also determined. As an additional step the in vivo effects of the compounds may be tested in animal models.Type: GrantFiled: May 5, 2000Date of Patent: May 18, 2004Assignee: Neurogen CorporationInventors: John Tallman, Dorothy Gallager, Kenneth Shaw, Geoffrey White, Marci Crandall, James Cassella, Lavanya Rajachandran, Pamela Albaugh